Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial (2018)
- Authors:
- USP affiliated authors: YASUNAKA, JENICER KAZUMI UMADA YOKOYAMA - ICB ; ULIANA, SILVIA RENI BORTOLIN - ICB
- Unidade: ICB
- DOI: 10.1111/tmi.13119
- Subjects: PARASITOLOGIA; LEISHMANIOSE CUTÂNEA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2018
- Source:
- Título: Tropical Medicine & International Health
- ISSN: 1365-3156
- Volume/Número/Paginação/Ano: v. 23, n. 9, p. 936-942, 2018
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MACHADO, Paulo R. L. et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Tropical Medicine & International Health, v. 23, n. 9, p. 936-942, 2018Tradução . . Disponível em: https://doi.org/10.1111/tmi.13119. Acesso em: 27 fev. 2026. -
APA
Machado, P. R. L., Ribeiro, C. S., França‐Costa, J., Dourado, M. E. F., Trinconi, C. T., Yokoyama‐Yasunaka, J. K. U., et al. (2018). Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Tropical Medicine & International Health, 23( 9), 936-942. doi:10.1111/tmi.13119 -
NLM
Machado PRL, Ribeiro CS, França‐Costa J, Dourado MEF, Trinconi CT, Yokoyama‐Yasunaka JKU, Malta‐Santos H, Borges VM, Carvalho EM, Uliana SRB. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial [Internet]. Tropical Medicine & International Health. 2018 ; 23( 9): 936-942.[citado 2026 fev. 27 ] Available from: https://doi.org/10.1111/tmi.13119 -
Vancouver
Machado PRL, Ribeiro CS, França‐Costa J, Dourado MEF, Trinconi CT, Yokoyama‐Yasunaka JKU, Malta‐Santos H, Borges VM, Carvalho EM, Uliana SRB. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial [Internet]. Tropical Medicine & International Health. 2018 ; 23( 9): 936-942.[citado 2026 fev. 27 ] Available from: https://doi.org/10.1111/tmi.13119 - Discovery of synthetic Leishmania Inhibitors by screening of a 2-arylbenzothiophene library
- Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool
- A dysflagellar mutant of Leishmania (Viannia) braziliensis isolated from a cutaneous leishmaniasis patient
- Combination therapy with Tamoxifen and Amphotericin B in experimental cutaneous Leishmaniasis
- In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B
- Topical tamoxifen in the therapy of cutaneous leishmaniasis
- Susceptibility to miltefosine in brazilian clinical isolates of Leishmania (Viannia) braziliensis
- Antileishmanial activity of the estrogen receptor modulator raloxifene
- Low plasma lipids are associated with relapsing and lethal Visceral Leishmaniasis in HIV-infected patients
- Leishmania is not prone to develop resistance to tamoxifen
Informações sobre o DOI: 10.1111/tmi.13119 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
